JP2024522175A - Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法 - Google Patents

Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法 Download PDF

Info

Publication number
JP2024522175A
JP2024522175A JP2023575701A JP2023575701A JP2024522175A JP 2024522175 A JP2024522175 A JP 2024522175A JP 2023575701 A JP2023575701 A JP 2023575701A JP 2023575701 A JP2023575701 A JP 2023575701A JP 2024522175 A JP2024522175 A JP 2024522175A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
weeks
seq
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522175A5 (enExample
Inventor
ミケーレ アン グリンバルデストン，
ディヴィヤ モハン，
アーメド ユスフ，
クリストファー ブライトリング，
ドロシー ジー－ウィング チェン，
デーヴィッド フォン チョイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024522175A publication Critical patent/JP2024522175A/ja
Publication of JP2024522175A5 publication Critical patent/JP2024522175A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023575701A 2021-06-11 2022-06-10 Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法 Pending JP2024522175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209624P 2021-06-11 2021-06-11
US63/209,624 2021-06-11
PCT/US2022/032979 WO2022261417A1 (en) 2021-06-11 2022-06-10 Method for treating chronic obstructive pulmonary disease with an st2 antagonist

Publications (2)

Publication Number Publication Date
JP2024522175A true JP2024522175A (ja) 2024-06-11
JP2024522175A5 JP2024522175A5 (enExample) 2025-06-17

Family

ID=82458702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575701A Pending JP2024522175A (ja) 2021-06-11 2022-06-10 Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法

Country Status (12)

Country Link
US (1) US20240228638A1 (enExample)
EP (1) EP4352101A1 (enExample)
JP (1) JP2024522175A (enExample)
KR (1) KR20240019831A (enExample)
CN (1) CN117980333A (enExample)
AU (1) AU2022289017A1 (enExample)
BR (1) BR112023025863A2 (enExample)
CA (1) CA3221924A1 (enExample)
IL (1) IL308597A (enExample)
MX (1) MX2023014658A (enExample)
TW (1) TW202317622A (enExample)
WO (1) WO2022261417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Limited ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
CN122121878A (zh) * 2023-09-06 2026-05-29 维罗纳制药有限公司 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIN SCI (LOND), vol. 133, no. 8, JPN6026026219, 2019, pages 983 - 996, ISSN: 0005891917 *
CLINICALTRIALS.GOV[ONLINE], ANTI-ST2 (MSTT1041A) IN COPD (COPD-ST2OP) (COPD-ST2OP), VIEWING V10, CLINICALTRIALS.GOV ID:NCT036150, JPN6026026220, 24 February 2021 (2021-02-24), ISSN: 0005891918 *

Also Published As

Publication number Publication date
TW202317622A (zh) 2023-05-01
BR112023025863A2 (pt) 2024-03-05
IL308597A (en) 2024-01-01
CA3221924A1 (en) 2022-12-15
AU2022289017A1 (en) 2023-11-30
AU2022289017A9 (en) 2023-12-07
KR20240019831A (ko) 2024-02-14
US20240228638A1 (en) 2024-07-11
EP4352101A1 (en) 2024-04-17
CN117980333A (zh) 2024-05-03
WO2022261417A1 (en) 2022-12-15
MX2023014658A (es) 2024-01-12

Similar Documents

Publication Publication Date Title
US20240228638A1 (en) Method for Treating Chronic Obstructive Pulmonary Disease With an ST2 Antagonist
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
EP2627673B1 (en) Therapies for improving pulmonary function
RU2713406C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP2017160203A (ja) 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
JP2025164767A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
CA3239667A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
HK40110471A (en) Method for treating chronic obstructive pulmonary disease with an st2 antagonist
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
EP4647084A1 (en) Method for treating asthma by using tslp antibody
WO2025120567A1 (en) Method of treatment of asthma
CN116635417A (zh) 白介素5结合蛋白给药方案
EA052377B1 (ru) Применение антитела, которое специфически связывает il-33, для лечения copd
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function
HK40007968A (en) Uses of il-13 antagonists for treating atopic dermatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623